Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease

The number of patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is increasing globally and is raising serious concerns regarding the increasing medical and economic burden incurred for their treatment. The progression of NASH to more severe conditions such as...

Full description

Bibliographic Details
Published in:Biomolecules
Main Authors: Shotaro Kamata, Akihiro Honda, Isao Ishii
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Subjects:
lanifibranor
saroglitazar
bezafibrate
pemafibrate
PPAR
dual/pan agonist
Online Access:https://www.mdpi.com/2218-273X/13/8/1264

Internet

https://www.mdpi.com/2218-273X/13/8/1264

Similar Items